Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ARTL

Artelo Biosciences Inc

Apr 21 • 10:42AM ET

4.19

-0.34 -7.40 %

Healthcare • Biotechnology • USA • NASD

Apr 20, 7:55 AMArtelo Biosciences' ART26.12 non-opioid pain candidate backed by European Journal of Pain data showing preclinical efficacy and favorable Phase 1 safety

Peers: CLSD ONCY LITS EPIX MBIO MTNB BPTH PULM VSTM

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-47.93	Insider Own	-	Shs Outstand	0.94M	Perf Week	-22.55%
Market Cap	3.94M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	0.70M	Perf Month	-47.43%
Enterprise Value	4.02M	PEG	-	EPS next Q	-	Inst Own	3.50%	Short Float	67.56%	Perf Quarter	-15.86%
Income	-12.88M	P/S	-	EPS this Y	-	Inst Trans	1.97%	Short Ratio	0.14	Perf Half Y	-66.67%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-343.49%	Short Interest	0.47M	Perf YTD	14.48%
Book/sh	-1.89	P/C	6.56	EPS next 5Y	-	ROE	-1625.11%	52W High	85.80 -95.12%	Perf Year	-77.18%
Cash/sh	0.64	P/FCF	-	EPS past 3/5Y	16.31% 35.60%	ROIC	-	52W Low	2.95 41.79%	Perf 3Y	-91.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.34% 31.85%	Perf 5Y	-98.67%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	12.62%	Oper. Margin	-	ATR (14)	1.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.17	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.57	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.17	EPS Q/Q	70.51%	SMA20	-31.96%	Beta	0.20	Target Price	54.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-17.10%	Rel Volume	0.50	Prev Close	4.53
Employees	7	LT Debt/Eq	-	Earnings	Feb 24 BMO	SMA200	-69.36%	Avg Volume	3.37M	Price	4.19
IPO	Nov 14, 2017	Option/Short	No / Yes	EPS/Sales Surpr.	-41.40% -	Trades		Volume	375,580	Change	-7.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-25	Upgrade	D. Boral Capital	Hold → Buy	$20
Feb-12-21	Initiated	Ladenburg Thalmann	Buy	$7

Apr-20-26 10:30AM	BC-Most Active Stocks (Associated Press)
07:50AM	Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile (GlobeNewswire)
Apr-07-26 07:50AM	Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.29%
Mar-30-26 04:46PM	Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.17% -13.17%
Mar-27-26 10:40AM	Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +230.41%
10:30AM	Loading…
10:30AM	BC-Most Active Stocks (Associated Press)
Mar-25-26 04:05PM	Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments (GlobeNewswire) -16.23% -34.23%
07:31AM	Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength (GlobeNewswire)
Mar-18-26 08:07AM	Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study (GlobeNewswire) +50.72%
07:41AM	Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients (GlobeNewswire)
Mar-07-26 08:13AM	Artelo Biosciences announces 3-for-1 reverse stock split (TipRanks)
Mar-06-26 08:00AM	Artelo Biosciences Announces Reverse Stock Split (GlobeNewswire)
Feb-24-26 08:00AM	Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results (GlobeNewswire)
Dec-23-25 09:00AM	Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate (GlobeNewswire)
Dec-03-25 08:30AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models (GlobeNewswire) -8.33%
08:00AM	Loading…
Nov-12-25 08:00AM	Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -8.16%
Nov-04-25 08:30AM	Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer (GlobeNewswire) -38.00%
Oct-27-25 08:00AM	Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer (GlobeNewswire)
Oct-15-25 09:15AM	Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit (GlobeNewswire)
Oct-01-25 04:05PM	Artelo Biosciences Announces Closing of $2.0 Million Public Offering (GlobeNewswire)
Sep-30-25 08:30AM	Artelo Biosciences Announces Pricing of $2.0 Million Public Offering (GlobeNewswire) -21.54%
Sep-29-25 07:15PM	Artelo Biosciences Announces Proposed Underwritten Public Offering (GlobeNewswire) +6.17%
08:30AM	Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference (GlobeNewswire)
Sep-10-25 08:30AM	Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms (GlobeNewswire)
Sep-08-25 09:49AM	Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls (The Fly)
Sep-05-25 04:05PM	Artelo Biosciences Announces Closing of $3.0 Million Public Offering (GlobeNewswire)
Sep-04-25 08:37AM	Artelo Biosciences Announces Pricing of $3.0 Million Public Offering (GlobeNewswire) -50.34%
Sep-03-25 04:35PM	Artelo Biosciences Announces Proposed Underwritten Public Offering (GlobeNewswire)
11:33AM	Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results (GlobeNewswire)
08:45AM	Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) (GlobeNewswire)
07:55AM	Loading…
Aug-25-25 07:55AM	Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain (GlobeNewswire)
Aug-13-25 08:00AM	Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 09:15AM	Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 (GlobeNewswire) +20.12%
Aug-04-25 07:30AM	Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset (GlobeNewswire)
Aug-01-25 07:45AM	Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression (GlobeNewswire) -14.00%
Jul-09-25 07:50AM	Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium (GlobeNewswire) +35.85%
07:20AM	Artelo Biosciences' ART12.11 Shows Promising Antidepressant Effects in Preclinical Study (Insider Monkey)
Jul-07-25 07:45AM	Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model (GlobeNewswire) +42.49%
Jun-30-25 07:45AM	Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain (GlobeNewswire) +95.43%
Jun-26-25 08:00AM	Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing (GlobeNewswire) +12.07%
Jun-11-25 08:30AM	Artelo Biosciences Announces Reverse Stock Split (GlobeNewswire) +6.19%
Jun-05-25 09:00AM	Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study (GlobeNewswire)
Jun-02-25 09:00AM	New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression (GlobeNewswire)
May-13-25 08:00AM	Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-28-25 08:45AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis (GlobeNewswire)
Apr-10-25 05:43AM	New Strong Sell Stocks for April 10th (Zacks) -10.63%
Mar-31-25 08:30AM	Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 (GlobeNewswire) -6.91%
Mar-28-25 03:39AM	New Strong Sell Stocks for March 28th (Zacks)
Mar-03-25 08:00AM	Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results (GlobeNewswire) -6.54%
Feb-14-25 09:00AM	Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex (GlobeNewswire) -14.39%
Feb-11-25 09:00AM	Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland (GlobeNewswire)
Jan-13-25 09:00AM	Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 (GlobeNewswire)
Dec-10-24 09:43AM	Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia (TipRanks)
Dec-09-24 09:15AM	Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia (GlobeNewswire) -5.39%
Nov-18-24 08:30AM	Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit (GlobeNewswire) +17.31%
Nov-13-24 08:30AM	Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium (GlobeNewswire) -5.98%
Nov-12-24 08:00AM	Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.42%
Nov-05-24 08:30AM	Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's Preclinical Screening Platform for Pain Program (GlobeNewswire) +9.66%
Oct-09-24 09:00AM	Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th (GlobeNewswire)
Sep-04-24 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 08:00AM	Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-15-24 08:30AM	Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor (GlobeNewswire)
Jul-03-24 09:00AM	Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jul-02-24 09:00AM	Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform (GlobeNewswire)
Jul-01-24 09:00AM	Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-04-24 08:30AM	Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society (GlobeNewswire)
May-29-24 08:30AM	Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 (GlobeNewswire)
May-13-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-10-24 09:00AM	Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th (GlobeNewswire)
Apr-23-24 08:30AM	Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy (GlobeNewswire)
Apr-22-24 08:30AM	Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time (GlobeNewswire)
Mar-25-24 01:53PM	ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023 (InvestorPlace)
08:00AM	Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 09:15AM	Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge (GlobeNewswire)
Feb-15-24 09:00AM	Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th (ACCESSWIRE) +6.13%
Jan-23-24 08:30AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy (GlobeNewswire)
Jan-08-24 08:30AM	Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12 (GlobeNewswire)
Dec-05-23 08:30AM	Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)
Nov-30-23 09:00AM	Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany (GlobeNewswire)
Nov-13-23 08:00AM	Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-23 09:00AM	Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers (GlobeNewswire) -8.33%
Nov-02-23 08:30AM	Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023 (GlobeNewswire)
Oct-04-23 08:30AM	Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia (GlobeNewswire)
Sep-13-23 08:30AM	Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th (GlobeNewswire)
Sep-07-23 08:00AM	Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12 (GlobeNewswire) -22.60%
Sep-06-23 09:00AM	Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th (GlobeNewswire) +27.03%
Sep-05-23 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th (GlobeNewswire)
Aug-10-23 08:00AM	Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-19-23 09:00AM	Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023 (GlobeNewswire)
Jul-10-23 08:30AM	Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11 (GlobeNewswire)
Jun-28-23 08:30AM	Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-27-23 08:30AM	Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-26-23 08:30AM	Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire)
Jun-07-23 08:30AM	Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium (GlobeNewswire) +10.26%
May-11-23 08:00AM	Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-23 08:30AM	Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire) -21.75%
Mar-31-23 08:00AM	Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update (GlobeNewswire) +7.91%
Feb-15-23 08:30AM	Artelo Biosciences to Present at MicroCap Rodeos Annual Winter Wonderland Best Ideas Virtual Investor Conference on February 22, 2023 (ACCESSWIRE)
Feb-02-23 09:00AM	Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss (GlobeNewswire)

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTL

Artelo Biosciences Inc

Upgrade your Finviz experience